Romore Idda, Ali Ali Mohamed, Semali Innocent, Mshinda Hassan, Tanner Marcel, Abdulla Salim
Swiss Tropical and Public health Institute, Socinstrasse 57, Postfach, 4002, Basel, Switzerland.
University of Basel, Basel, Switzerland.
Malar J. 2015 Sep 17;14:355. doi: 10.1186/s12936-015-0889-7.
Clinical trials of the RTS,S malaria vaccine have completed Phase III and the vaccine is on track for registration. Before making decisions about implementation, it is essential to prepare the ground for introducing the vaccine by assessing awareness and willingness to use malaria vaccines and to provide policy makers with evidence-based information on the best strategies to engage communities to manage the introduction of malaria vaccine in Tanzania.
In November 2011, as part of a large cross-sectional study of all 23 regions of Tanzania (mainland Tanzania and Zanzibar) was conducted during Tanzanian Integrated Measles Campaign (IMC) survey. In this study, the variables of interests were awareness and willingness to use a malaria vaccine. The main outcome measure was willingness to use a malaria vaccine. Logistic regression was used to examine the influence of predictive factors.
A representative sample of 5502 (out of 6210) women, aged 18 years or older and with children under 11 months old, was selected to participate, using random sampling probability. Awareness of the forthcoming malaria vaccine, 11.8 % of participants in mainland Tanzania responded affirmatively, compared to 3.4 % in Zanzibar (p value <0.0001). 94.5 % of all respondents were willing to vaccinate their children against malaria, with a slight difference between mainland Tanzania (94.3 %) and Zanzibar (96.8 %) (p value = 0.0167).
Although mothers had low awareness and high willingness to use malaria vaccine, still availability of malaria vaccine RTS,S will compliment other existing malaria interventions and it will be implemented through the Immunization, Vaccines and Biologicals (IVB) programme (formerly EPI). The information generated from this study can aid policy makers in planning and setting priorities for introducing and implementing the malaria vaccine.
RTS,S疟疾疫苗的临床试验已完成III期，该疫苗正按计划进行注册。在做出实施决策之前，通过评估对疟疾疫苗的知晓度和使用意愿，为引入该疫苗做好准备，并向政策制定者提供基于证据的信息，说明在坦桑尼亚让社区参与管理疟疾疫苗引入的最佳策略，这至关重要。
2011年11月，作为对坦桑尼亚所有23个地区（坦桑尼亚大陆和桑给巴尔）进行的一项大型横断面研究的一部分，在坦桑尼亚综合麻疹运动（IMC）调查期间开展了此项研究。在本研究中，感兴趣的变量是对疟疾疫苗的知晓度和使用意愿。主要结局指标是使用疟疾疫苗的意愿。采用逻辑回归分析来检验预测因素的影响。
采用随机抽样概率，选取了5502名（共6210名）年龄在18岁及以上且有11个月以下儿童的女性作为代表性样本参与研究。对于即将推出的疟疾疫苗，坦桑尼亚大陆11.8%的参与者给出肯定答复，而桑给巴尔为3.4%（p值<0.0001）。所有受访者中有94.5%愿意为其子女接种疟疾疫苗，坦桑尼亚大陆（94.3%）和桑给巴尔（96.8%）之间略有差异（p值=0.0167）。
尽管母亲们对疟疾疫苗的知晓度较低，但使用意愿较高，不过疟疾疫苗RTS,S仍然会补充其他现有的疟疾干预措施，并将通过免疫、疫苗和生物制品（IVB）计划（原扩大免疫规划）来实施。本研究产生的信息有助于政策制定者规划和确定引入及实施疟疾疫苗的优先事项。
